Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis
- 1 February 2002
- journal article
- Published by Elsevier in Kidney International
- Vol. 61 (2) , 473-480
- https://doi.org/10.1046/j.1523-1755.2002.00154.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathyKidney International, 2000
- Renoprotective therapy: titration against urinary protein excretionThe Lancet, 1999
- Proteinuria as a Mediator of Tubulointerstitial InjuryKidney and Blood Pressure Research, 1999
- Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trialThe Lancet, 1998
- Differences in Tissue Angiotensin II–Forming Pathways by Species and Organs In VitroHypertension, 1998
- Antiproteinuric Effect Predicts Renal Protection by Angiotensin-Converting Enzyme Inhibition in Rats with Established Adriamycin NephrosisClinical Science, 1996
- Mechanisms of angiotensin H formation in humansEuropean Heart Journal, 1995
- Pharmacology of angiotensin II receptors in the kidneyKidney International, 1994
- Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal DiseaseAmerican Journal of Kidney Diseases, 1993
- Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinoprilKidney International, 1989